Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rossignol Julien, Ouedrani Amani, Livideanu Cristina Bulai, Barete Stéphane, Terriou Louis, Launay David, Lemal Richard, Greco Celine, Frenzel Laurent, Meni Cecile, Bodemere-Skandalis Christine, Polivka Laura, Collange Anne-Florence, Hachichi Hassiba, Bouzourine Sonia, Messaoud Djazira Nait, Negretto Mathilde, Vendrame Laurence, Jambou Marguerite, Gousseff Marie, Durupt Stéphane, Lega Jean-Christophe, Durand Jean-Marc, Gaudy Caroline, Damaj Gandhi, Gourin Marie-Pierre, Hamidou Mohamed, Bouillet Laurence, Le Mouel Edwige, Maria Alexandre, Zunic Patricia, Cabrera Quentin, Vincent Denis, Lavigne Christian, Riviere Etienne, Gourguechon Clement, Courbebaisse Marie, Lebeaux David, Parfait Béatrice, Friedlander Gérard, Brignier Anne, Lhermitte Ludovic, Molina Thierry Jo, Bruneau Julie, Agopian Julie, Dubreuil Patrice, Ranta Dana, Mania Alexandre, Arock Michel, Staropoli Isabelle, Tournilhac Olivier, Lortholary Olivier, Schwartz Olivier, Chatenoud Lucienne, Hermine Olivier
Аннотация
OBJECTIVE: To study a comprehensive range of outcomes in patients with cMCAD with PCR- or serologically confirmed coronavirus disease 2019 and to characterize the specific anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune response in this setting.
METHODS: Clinical follow-up and outcome data were collected prospectively over a 12-month period by members of the French Centre de Référence des Mastocytoses rare disease network. Anti-SARS-CoV-2-specific T-cell activity was measured with an ELISA, and humoral responses were evaluated by assaying circulating levels of specific IgG, IgA, and neutralizing antibodies.
RESULTS: Overall, 32 patients with cMCAD were evaluated. None required noninvasive or mechanical ventilation. Two patients were admitted to hospital for oxygen and steroid therapy. The SARS-CoV-2-specific immune response was characterized in 21 of the 32 patients. Most had high counts of circulating SARS-CoV-2-specific, IFN-γ-producing T cells and high titers of neutralizing antispike IgGs. The patients frequently showed spontaneous T-cell IFN-γ production in the absence of stimulation; this production was correlated with basal circulating tryptase levels (a marker of the mast cell burden).
CONCLUSIONS: Patients with cMCADs might not be at risk of severe coronavirus disease 2019, perhaps due to their spontaneous production of IFN-γ.